



Singapore Mortality Experience 2004 – 2008 Mortality Work Group

Singapore, AA Symposium 4 November 2010

Agenda

- Data received
- Preliminary Results Mortality
- Population Experience
- Critical Illness Graduated Table
- TPD Graduated Table
- Use of the Results





The Investigation

- After a few false starts final data received from all companies.
- Issue was Death with 100% Critical Illness acceleration.
- Are able to produce tables for
 - Mortality (Both WoL/End and Term)
 - Critical Illness
 - TPD



Data - Years 2003 - 2008

- We received exposure and claims data split:
 - Age
 - Duration 0,1,2,3,4 and 5+
 - Gender
 - Investment Linked /Non Investment Linked
 - WoL and Endowment/Term
 - Benefit Type (Mortality, CI 100% acceleration, CI not 100% acceleration, TPD)
 - Medical / Non Medical



Data – Exposure

| DEATH | COVER | Average | annual exposure | | |
|---------|---------|------------|-----------------|---------|-----------|
| | | | | | |
| Females | 3 | | | | |
| | Non IL | | Non Medical | Medical | Total |
| | | WOL | 1,773,844 | 148,212 | 1,922,056 |
| | | Term | 81,356 | 17,941 | 99,297 |
| | | | 1,855,200 | 166,153 | 2,021,353 |
| | Investm | ent Linked | | | |
| | | WOL | 553,526 | 12,181 | 565,707 |
| | | Term | 64 | 5 | 69 |
| | | | 553,590 | 12,186 | 565,776 |
| Males | | | | | |
| | Non IL | | Non Medical | Medical | Total |
| | | WOL | 1,534,884 | 165,897 | 1,700,781 |
| | | Term | 104,804 | 34,352 | 139,156 |
| | | | 1,639,688 | 200,249 | 1,839,937 |
| | Investm | ent Linked | | | |
| | | WOL | 609,696 | 17,984 | 627,680 |
| | | Term | 53 | 6 | 59 |
| | | | 609,749 | 17,990 | 627,739 |
| | | | | | |
| TOTAL | | | 4,658,227 | 396,578 | 5,054,805 |



Data – Exposure

| CRITIC | AL ILLN | ESS WITH | l 100% accelerat | ion Average A | nnual Exposure | |
|---------|----------|------------|------------------|---------------|----------------|--|
| Females | <u> </u> | | | | | |
| | Non IL | | Non Medical | Medical | Total | |
| | | WOL | 484,643 | 47,643 | 532,286 | |
| | | Term | 11,373 | 1,087 | 12,460 | |
| | | | 496,016 | 48,730 | 544,746 | |
| | Investm | ent Linked | | | | |
| | | WOL | 83,396 | 3,019 | 86,415 | |
| | | Term | - | - | - | |
| | | | 83,396 | 3,019 | 86,415 | |
| Males | | | | | | |
| | Non IL | | Non Medical | Medical | Total | |
| | | WOL | 380,340 | 41,059 | 421,399 | |
| | | Term | 15,083 | 3,595 | 18,678 | |
| | | | 395,423 | 44,654 | 440,077 | |
| | Investm | ent Linked | | | | |
| | | WOL | 73,320 | 3,689 | 77,009 | |
| | | Term | - | - | - | |
| | | | 73,320 | 3,689 | 77,009 | |
| TOTAL | | | 1,048,155 | 100,092 | 1,148,247 | |





Data – Exposure

| DEATH | DEATH COVER EXCLUDING 100% CI Business Average Annual Exposure | | | | | | | | |
|---------|--|------------|-------------|---------|-----------|--|--|--|--|
| Females | 3 | | | | | | | | |
| | Non IL | | Non Medical | Medical | Total | | | | |
| | | WOL | 1,289,201 | 100,569 | 1,389,770 | | | | |
| | | Term | 69,983 | 16,854 | 86,837 | | | | |
| | | | 1,359,184 | 117,423 | 1,476,607 | | | | |
| | Investm | ent Linked | | | | | | | |
| | | WOL | 470,130 | 9,162 | 479,292 | | | | |
| | | Term | 64 | 5 | 69 | | | | |
| | | | 470,194 | 9,167 | 479,361 | | | | |
| Males | | | | | | | | | |
| | Non IL | | Non Medical | Medical | Total | | | | |
| | | WOL | 1,154,544 | 124,838 | 1,279,382 | | | | |
| | | Term | 89,721 | 30,757 | 120,478 | | | | |
| | | | 1,244,265 | 155,595 | 1,399,860 | | | | |
| | Investm | ent Linked | | | | | | | |
| | | WOL | 536,376 | 14,295 | 550,671 | | | | |
| | | Term | 53 | 6 | 59 | | | | |
| | | | 536,429 | 14,301 | 550,730 | | | | |
| TOTAL | | | 3,610,072 | 296,486 | 3,906,558 | | | | |





- We followed the previous decision to combine the Medical and Non Medical experience.
- We also looked at the selection effect on mortality and initially agreed on a 2 year effect:
 - Actual/Expected(S9702)
 - Year 0 : 59% Male, 27% Female
 - Year 1 : 71% Male, 52% Female
 - Year 2 : 72% Male, 54% Female
 - Year 3 : 74% Male, 59% Female
 - Year 4: 73% Male, 73% Female
 - Year 5+ 73% Male, 76% Female





So the comparison with S9702 is with:

- Whole Life and Endowment
- Investment Linked and Non Investment Linked
- Duration 2 years and more
- Does not look at Juveniles
- Medical and Non Medical combined
- Excludes policies with 100% Accelerating Critical Illness





Comparing actual to expected (S9702) we get:

| | | 2004 | 2005 | 2006 | 2007 | 2008 | Overall |
|--------|----------|-------|-------|-------|-------|-------|---------|
| Male | Expected | 1,906 | 2,070 | 2,236 | 2,360 | 2,465 | 11,037 |
| | Actual | 1,390 | 1,704 | 1,617 | 1,608 | 1,704 | 8,023 |
| | | 72.9% | 82.3% | 72.3% | 68.1% | 69.1% | 72.7% |
| | | | | | | | |
| | | | | | | | |
| | | 2004 | 2005 | 2006 | 2007 | 2008 | Overall |
| Female | Expected | 1,214 | 1,360 | 1,498 | 1,586 | 1,662 | 7,320 |
| | Actual | 860 | 948 | 1,057 | 1,109 | 1,093 | 5,067 |
| | | 70.9% | 69.7% | 70.6% | 69.9% | 65.8% | 69.2% |





Looking at IL Whole Life/Endowment and Term separately:

| | | IL WoL/End | Non IL Term |
|--------|----------|------------|-------------|
| Male | Expected | 2,275 | 609 |
| | Actual | 1,991 | 388 |
| | | 87.5% | 63.7% |
| | | | - |
| Female | Expected | 1,295 | 246 |
| | Actual | 945 | 152 |
| | | 72.9% | 61.8% |



Population Mortality Improvement

| | 1984-88 to | 1989-90 | 989-93 t | o 1997-10 | 997-02 t | o 2003 -0 | 989-93 t | o 2003-08 |
|-------------|------------|------------|----------|------------|----------|------------------|----------|-----------|
| Age Last | Male | Femal e | Male | Femal e | Male | Femal e | Male | Female |
| 15 - 19 | -7.31% | -5.92% | -4.03% | -0.57% | -3.29% | -6.05% | -3.72% | -2.88% |
| 20 - 24 | -6.44% | -3.75% | -1.24% | -4.81% | -2.14% | 2.11% | -1.62% | -2.00% |
| 25 - 29 | -12.05% | -6.89% | 0.32% | -3.88% | -2.39% | -2.99% | -0.81% | -3.51% |
| 30 - 34 | -6.51% | -6.41% | -2.38% | -2.54% | -2.85% | -4.88% | -2.57% | -3.51% |
| 35 - 39 | -8.28% | -5.25% | -1.39% | -2.97% | -2.75% | -4.28% | -1.95% | -3.51% |
| 40 - 44 | -6.12% | -2.30% | -2.34% | -4.74% | -1.86% | -1.18% | -2.15% | -3.28% |
| 45 - 49 | -5.06% | -5.02% | -3.74% | -3.00% | -1.42% | -3.03% | -2.79% | -3.01% |
| 50 - 54 | -5.09% | -4.65% | -4.23% | -3.74% | -1.99% | -2.71% | -3.31% | -3.31% |
| 55 - 59 | -4.88% | -3.22% | -4.01% | -4.15% | -3.18% | -3.05% | -3.67% | -3.69% |
| 60 - 64 | -2.87% | -4.17% | -3.62% | -3.25% | -3.84% | -4.18% | -3.71% | -3.64% |
| 65 - 69 | -3.23% | -3.38% | -2.46% | -2.62% | -3.37% | -4.89% | -2.84% | -3.57% |
| eighted A | -6.97% | -4.93% | -2.50% | -3.35% | -2.51% | -3.14% | -2.59% | -3.25% |





Critical Illness Exposure

| CRITICA | AL ILLN | ESS WITH 10 | 0% accelerat | ion | |
|--------------|---------|-------------|--------------|---------|-----------|
| | | | | | |
| Females | | | | | |
| | Non IL | | Non Medica | Medical | Total |
| | | WOL | 484,643 | 47,643 | 532,286 |
| | | Term | 11,373 | 1,087 | 12,460 |
| | | | 496,016 | 48,730 | 544,746 |
| | Investm | ent Linked | | | |
| | | WOL | 83,396 | 3,019 | 86,415 |
| | | Term | - | - | - |
| | | | 83,396 | 3,019 | 86,415 |
| Males | | | | | |
| | Non IL | | Non Medica | Medical | Total |
| | | WOL | 380,340 | 41,059 | 421,399 |
| | | Term | 15,083 | 3,595 | 18,678 |
| | | | 395,423 | 44,654 | 440,077 |
| | Investm | ent Linked | | | |
| | | WOL | 73,320 | 3,689 | 77,009 |
| | | Term | - | - | - |
| | | | 73,320 | 3,689 | 77,009 |
| TOTAL | | | 1,048,155 | 100,092 | 1,148,247 |





Critical Illness Exposure

| CRITICA | AL ILLN | ESS WITHOUT | 100% acce | leration | |
|---------|---------|-------------|------------|----------|---------|
| | | | | | |
| Females | | | | | |
| | Non IL | | Non Medica | Medical | Total |
| | | WOL | 112,089 | 12,726 | 124,815 |
| | | Term | 455 | 278 | 733 |
| | | | 112,544 | 13,004 | 125,548 |
| | Investm | ent Linked | | | |
| | | WOL | 20,526 | 3,371 | 23,897 |
| | | Term | - | - | - |
| | | | 20,526 | 3,371 | 23,897 |
| Males | | | | | |
| | Non IL | | Non Medica | Medical | Total |
| | | WOL | 98,013 | 13,092 | 111,105 |
| | | Term | 534 | 496 | 1,030 |
| | | | 98,547 | 13,588 | 112,135 |
| | Investm | ent Linked | | | |
| | | WOL | 21,118 | 3,911 | 25,029 |
| | | Term | - | - | - |
| | | | 21,118 | 3,911 | 25,029 |
| TOTAL | | | 252,735 | 33,874 | 286,609 |





Critical Illness Exposure

| TOTAL | CRITICA | AL ILLNESS | | | |
|---------|---------|------------|------------|---------|-----------|
| Females | | | | | |
| | Non IL | | Non Medica | Medical | Total |
| | | WOL | 596,732 | 60,369 | 657,101 |
| | | Term | 11,828 | 1,365 | 13,193 |
| | | | 608,560 | 61,734 | 670,294 |
| | Investm | ent Linked | | | |
| | | WOL | 103,922 | 6,390 | 110,312 |
| | | Term | - | - | - |
| | | | 103,922 | 6,390 | 110,312 |
| Males | | | | | |
| | Non IL | | Non Medica | Medical | Total |
| | | WOL | 478,353 | 54,151 | 532,504 |
| | | Term | 15,617 | 4,091 | 19,708 |
| | | | 493,970 | 58,242 | 552,212 |
| | Investm | ent Linked | | | |
| | | WOL | 94,438 | 7,600 | 102,038 |
| | | Term | - | - | - |
| | | | 94,438 | 7,600 | 102,038 |
| TOTAL | | | 1,300,890 | 133,966 | 1,434,856 |





Critical Illness Results (Acc plus Add)

| Sample | Sample Graduated Critical Illness Rates per 1000 | | | | | | | |
|--------|--|--------|---------|---------|---------|--|--|--|
| Age | | | | | | | | |
| Last | | Males | % S9702 | Females | % S9702 | | | |
| 5 | | 0.295 | NA | 0.265 | NA | | | |
| 15 | | 0.451 | 244% | 0.335 | 216% | | | |
| 25 | | 0.269 | 58% | 0.301 | 151% | | | |
| 35 | | 0.389 | 76% | 0.662 | 169% | | | |
| 45 | | 1.674 | 131% | 2.341 | 259% | | | |
| 55 | | 4.871 | 135% | 4.371 | 187% | | | |
| 65 | | 11.995 | 104% | 8.097 | 147% | | | |
| 75 | | 33.201 | 109% | 16.492 | 77% | | | |





TPD Exposure

| TPD | | | | | |
|---------|---------|------------|-------------|---------|-----------|
| | | | | | |
| Females | | | | | |
| | Non IL | | Non Medical | Medical | Total |
| | | WOL | 1,672,878 | 141,205 | 1,814,083 |
| | | Term | 69,403 | 16,411 | 85,814 |
| | | | 1,742,281 | 157,616 | 1,899,897 |
| | Investm | ent Linked | | | |
| | | WOL | 251,095 | 7,781 | 258,876 |
| | | Term | - | - | - |
| | | | 251,095 | 7,781 | 258,876 |
| Males | | | | | |
| | Non IL | | Non Medical | Medical | Total |
| | | WOL | 1,460,340 | 158,735 | 1,619,075 |
| | | Term | 89,403 | 31,002 | 120,405 |
| | | | 1,549,743 | 189,737 | 1,739,480 |
| | Investm | ent Linked | | | |
| | | WOL | 271,965 | 10,099 | 282,064 |
| | | Term | - | - | - |
| | | | 271,965 | 10,099 | 282,064 |
| TOTAL | | | 3,815,084 | 365,233 | 4,180,317 |





TPD Results

Sample result from a graduated table.

| Sample Graduated TPD Rates per 1000 | | | | | | | | |
|-------------------------------------|-------|---------|---------|---------|--|--|--|--|
| Age | | | | | | | | |
| Last | Males | % S9702 | Females | % S9702 | | | | |
| 15 | 0.049 | 27% | 0.028 | 18% | | | | |
| 25 | 0.050 | 11% | 0.032 | 16% | | | | |
| 35 | 0.059 | 12% | 0.050 | 13% | | | | |
| 45 | 0.164 | 13% | 0.109 | 12% | | | | |
| 55 | 0.561 | 16% | 0.293 | 13% | | | | |



Next Steps

Results need careful checking.

Need to decide an approach to TPD impact.

Should consider whether a separate Critical Illness table is valid.





Thank you

To the Working Group

To the MAS

To the Contributors



